ACTA1 and breast carcinoma: Røgenes et al. developed and validated a 42-marker IMC panel specifically for studying CAF niches in breast cancer, which included key CAF markers such as α-SMA, FAP, and PDGFR, as well as functional markers including YAP1 and pSMAD2 [71].